Q1 2025 AtriCure Inc Earnings Call Transcript
Key Points
- AtriCure Inc (ATRC) reported a 14% growth in total revenue for the first quarter, reaching $124 million, driven by strong performance in pain management and appendage management franchises.
- The company achieved a significant improvement in profitability, with adjusted EBITDA increasing by more than 200% from the first quarter of 2024, reaching $9 million.
- AtriCure Inc (ATRC) received 510(k) clearance for its minimally invasive AtriClip PRO-Mini device, which is 60% smaller than the next lowest-profile device, enhancing visualization and precise placement.
- The company's Cryo Nerve Block therapy for pain management saw a 39% growth in the first quarter, with the cryoSPHERE MAX and cryoSPHERE+ probes driving broader use and interest from new accounts.
- AtriCure Inc (ATRC) is expanding its market with the recent FDA 510(k) clearance of the cryoXT probe, designed for extremity amputations, offering an opioid-free solution for phantom and residual limb pain.
- Minimally invasive ablation sales declined by approximately 31% over the first quarter of 2024, due to pressure from the adoption of PFA catheters.
- The company continues to face downward pressure in the US market for Hybrid AF therapy, despite strong growth in Europe.
- Operating expenses increased by 6.9% from the first quarter of 2024, driven by continued enrollment in the LeAAPS clinical trial and increased headcount for product development.
- Despite strong performance, AtriCure Inc (ATRC) reported a loss per share of $0.14 in the first quarter of 2025, compared to a loss per share of $0.28 in the first quarter of 2024.
- The company anticipates continued pressure on its minimally invasive ablation sales due to the widespread adoption of PFA, impacting near-term growth.
Good afternoon and welcome to AtriCure's First Quarter 2025 Earnings Conference Call. This call is being recorded for replay purposes. (Operator Instructions)
I would now like to turn the call over to Marissa Bych from the Gilmartin Group for a few introductory comments.
Thank you. By now, you should have received a copy of the earnings press release. If you have not received a copy, please call 513-644-4484 to have one emailed to you.
Before we begin today, let me remind you that the company's remarks include forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control, including risks and uncertainties described from time to time in AtriCure's SEC filings. These statements include, but are not limited to, financial expectations and guidance, expectations regarding the potential market opportunity for AtriCure's franchises and growth initiatives, future product approvals and clearances, competition,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
